Efficacy and Safety of Switching from Low-Dose Statin to High-Intensity Statin for Primary Prevention in Type 2 Diabetes: A Randomized Controlled Trial

Nuntakorn Thongtang, Jirasak Piyapromdee, Natthakan Tangkittikasem, Kittichai Samaithongcharoen, Nithiwat Srikanchanawat, Sutin Sriussadaporn Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandCorrespondence: N...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Thongtang N, Piyapromdee J, Tangkittikasem N, Samaithongcharoen K, Srikanchanawat N, Sriussadaporn S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	efficacy safety high-intensity statin primary prevention thai patients type 2 diabetes Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/39eb2b7810c149ce9955e1487e169e7f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:39eb2b7810c149ce9955e1487e169e7f
record_format	dspace
spelling	oai:doaj.org-article:39eb2b7810c149ce9955e1487e169e7f2021-12-02T08:38:29ZEfficacy and Safety of Switching from Low-Dose Statin to High-Intensity Statin for Primary Prevention in Type 2 Diabetes: A Randomized Controlled Trial1178-7007https://doaj.org/article/39eb2b7810c149ce9955e1487e169e7f2020-02-01T00:00:00Zhttps://www.dovepress.com/efficacy-and-safety-of-switching-from-low-dose-statin-to-high-intensit-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Nuntakorn Thongtang, Jirasak Piyapromdee, Natthakan Tangkittikasem, Kittichai Samaithongcharoen, Nithiwat Srikanchanawat, Sutin Sriussadaporn Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandCorrespondence: Nuntakorn ThongtangDivision of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok 10700, ThailandTel +66 2-419-7799Fax +66 2-419-7792Email nuntakorn@hotmail.comIntroduction: Statin intensification is required in patients who have high-risk for cardiovascular events. However, it is unclear if this is needed in whom plasma LDL-C target was achieved with low-dose statin for primary prevention. We investigated the efficacy and safety of switching from low-dose statin to high-intensity statin among type 2 diabetes (T2D) who had achieved plasma LDL-C < 100 mg/dl with low-dose statin treatment.Methods: T2D patients with no atherosclerotic cardiovascular disease who had plasma LDL-C level < 100 mg/dl while taking simvastatin ≤ 20 mg/day were randomized to continue using the same dosage of simvastatin (low-dose statin group; LS) for 12 weeks, or to switch to atorvastatin 40 mg/day for 6 weeks, and then, if tolerated, to atorvastatin 80 mg/day for 6 weeks (high-intensity statin group; HS). Biochemical test and adverse events were evaluated at baseline, 6 weeks, and 12 weeks.Results: One hundred and fifty patients (76 LS, 74 HS, mean age 58.9± 8.9 years, 72% female) were included. The mean baseline plasma LDL-C level on statin was slightly higher in the HS group (71.9± 13.6 vs. 68.1± 14.2 mg/dl, p=0.09). The HS group had a significantly lower plasma LDL-C level at both 6 and 12 weeks (both p< 0.001). Plasma LDL-C < 40 mg/dl was found more frequently in the HS group (23.0% vs. 3.9%, p< 0.001). Discontinuation of statin due to adverse effects was more frequent in the HS group (5.4% vs. 1.3%, p=0.38 for atorvastatin 40 mg/day, 12.2% vs. 1.3%, p=0.03 for atorvastatin 80 mg/day). No serious adverse events were observed in either group.Conclusion: Switching from low-dose statins to high-intensity statins resulted in a significant reduction in plasma LDL-C levels, and was fairly well tolerated during a 12-week study period.Keywords: efficacy, safety, high-intensity statin, primary prevention, Thai patients, type 2 diabetesThongtang NPiyapromdee JTangkittikasem NSamaithongcharoen KSrikanchanawat NSriussadaporn SDove Medical Pressarticleefficacysafetyhigh-intensity statinprimary preventionthai patientstype 2 diabetesSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 13, Pp 423-431 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	efficacy safety high-intensity statin primary prevention thai patients type 2 diabetes Specialties of internal medicine RC581-951
spellingShingle	efficacy safety high-intensity statin primary prevention thai patients type 2 diabetes Specialties of internal medicine RC581-951 Thongtang N Piyapromdee J Tangkittikasem N Samaithongcharoen K Srikanchanawat N Sriussadaporn S Efficacy and Safety of Switching from Low-Dose Statin to High-Intensity Statin for Primary Prevention in Type 2 Diabetes: A Randomized Controlled Trial
description	Nuntakorn Thongtang, Jirasak Piyapromdee, Natthakan Tangkittikasem, Kittichai Samaithongcharoen, Nithiwat Srikanchanawat, Sutin Sriussadaporn Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandCorrespondence: Nuntakorn ThongtangDivision of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok 10700, ThailandTel +66 2-419-7799Fax +66 2-419-7792Email nuntakorn@hotmail.comIntroduction: Statin intensification is required in patients who have high-risk for cardiovascular events. However, it is unclear if this is needed in whom plasma LDL-C target was achieved with low-dose statin for primary prevention. We investigated the efficacy and safety of switching from low-dose statin to high-intensity statin among type 2 diabetes (T2D) who had achieved plasma LDL-C < 100 mg/dl with low-dose statin treatment.Methods: T2D patients with no atherosclerotic cardiovascular disease who had plasma LDL-C level < 100 mg/dl while taking simvastatin ≤ 20 mg/day were randomized to continue using the same dosage of simvastatin (low-dose statin group; LS) for 12 weeks, or to switch to atorvastatin 40 mg/day for 6 weeks, and then, if tolerated, to atorvastatin 80 mg/day for 6 weeks (high-intensity statin group; HS). Biochemical test and adverse events were evaluated at baseline, 6 weeks, and 12 weeks.Results: One hundred and fifty patients (76 LS, 74 HS, mean age 58.9± 8.9 years, 72% female) were included. The mean baseline plasma LDL-C level on statin was slightly higher in the HS group (71.9± 13.6 vs. 68.1± 14.2 mg/dl, p=0.09). The HS group had a significantly lower plasma LDL-C level at both 6 and 12 weeks (both p< 0.001). Plasma LDL-C < 40 mg/dl was found more frequently in the HS group (23.0% vs. 3.9%, p< 0.001). Discontinuation of statin due to adverse effects was more frequent in the HS group (5.4% vs. 1.3%, p=0.38 for atorvastatin 40 mg/day, 12.2% vs. 1.3%, p=0.03 for atorvastatin 80 mg/day). No serious adverse events were observed in either group.Conclusion: Switching from low-dose statins to high-intensity statins resulted in a significant reduction in plasma LDL-C levels, and was fairly well tolerated during a 12-week study period.Keywords: efficacy, safety, high-intensity statin, primary prevention, Thai patients, type 2 diabetes
format	article
author	Thongtang N Piyapromdee J Tangkittikasem N Samaithongcharoen K Srikanchanawat N Sriussadaporn S
author_facet	Thongtang N Piyapromdee J Tangkittikasem N Samaithongcharoen K Srikanchanawat N Sriussadaporn S
author_sort	Thongtang N
title	Efficacy and Safety of Switching from Low-Dose Statin to High-Intensity Statin for Primary Prevention in Type 2 Diabetes: A Randomized Controlled Trial
title_short	Efficacy and Safety of Switching from Low-Dose Statin to High-Intensity Statin for Primary Prevention in Type 2 Diabetes: A Randomized Controlled Trial
title_full	Efficacy and Safety of Switching from Low-Dose Statin to High-Intensity Statin for Primary Prevention in Type 2 Diabetes: A Randomized Controlled Trial
title_fullStr	Efficacy and Safety of Switching from Low-Dose Statin to High-Intensity Statin for Primary Prevention in Type 2 Diabetes: A Randomized Controlled Trial
title_full_unstemmed	Efficacy and Safety of Switching from Low-Dose Statin to High-Intensity Statin for Primary Prevention in Type 2 Diabetes: A Randomized Controlled Trial
title_sort	efficacy and safety of switching from low-dose statin to high-intensity statin for primary prevention in type 2 diabetes: a randomized controlled trial
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/39eb2b7810c149ce9955e1487e169e7f
work_keys_str_mv	AT thongtangn efficacyandsafetyofswitchingfromlowdosestatintohighintensitystatinforprimarypreventionintype2diabetesarandomizedcontrolledtrial AT piyapromdeej efficacyandsafetyofswitchingfromlowdosestatintohighintensitystatinforprimarypreventionintype2diabetesarandomizedcontrolledtrial AT tangkittikasemn efficacyandsafetyofswitchingfromlowdosestatintohighintensitystatinforprimarypreventionintype2diabetesarandomizedcontrolledtrial AT samaithongcharoenk efficacyandsafetyofswitchingfromlowdosestatintohighintensitystatinforprimarypreventionintype2diabetesarandomizedcontrolledtrial AT srikanchanawatn efficacyandsafetyofswitchingfromlowdosestatintohighintensitystatinforprimarypreventionintype2diabetesarandomizedcontrolledtrial AT sriussadaporns efficacyandsafetyofswitchingfromlowdosestatintohighintensitystatinforprimarypreventionintype2diabetesarandomizedcontrolledtrial
_version_	1718398411286249472

Efficacy and Safety of Switching from Low-Dose Statin to High-Intensity Statin for Primary Prevention in Type 2 Diabetes: A Randomized Controlled Trial

Ejemplares similares